137 related articles for article (PubMed ID: 33129747)
21. Significance of CD34/CD123 expression in detection of minimal residual disease in B-ACUTE lymphoblastic leukemia in children.
Zeidan MA; Kamal HM; El Shabrawy DA; Esh AM; Sattar RH
Blood Cells Mol Dis; 2016 Jul; 59():113-8. PubMed ID: 27282579
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy.
Du W; Li J; Liu W; He Y; Yao J; Liu Y; Lin J; Zheng J
Tumour Biol; 2016 Mar; 37(3):3817-21. PubMed ID: 26474588
[TBL] [Abstract][Full Text] [Related]
23. A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML.
Das N; Gupta R; Gupta SK; Bakhshi S; Malhotra A; Rai S; Singh S; Prajapati VK; Sahoo RK; Gogia A; Sharma A; Kumar L
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e673-e684. PubMed ID: 32561191
[TBL] [Abstract][Full Text] [Related]
24. Aberrant activation-induced cytidine deaminase expression in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.
Shi Y; Zhao X; Durkin L; Rogers HJ; Hsi ED
Hum Pathol; 2016 Jun; 52():173-8. PubMed ID: 26980048
[TBL] [Abstract][Full Text] [Related]
25. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.
Russell LJ; Capasso M; Vater I; Akasaka T; Bernard OA; Calasanz MJ; Chandrasekaran T; Chapiro E; Gesk S; Griffiths M; Guttery DS; Haferlach C; Harder L; Heidenreich O; Irving J; Kearney L; Nguyen-Khac F; Machado L; Minto L; Majid A; Moorman AV; Morrison H; Rand V; Strefford JC; Schwab C; Tönnies H; Dyer MJ; Siebert R; Harrison CJ
Blood; 2009 Sep; 114(13):2688-98. PubMed ID: 19641190
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients.
Aref S; Azmy E; El Ghannam D; Haroun M; Ibrahim L; Sabry M
Cancer Biomark; 2020; 29(1):9-16. PubMed ID: 32417762
[TBL] [Abstract][Full Text] [Related]
28. CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease.
Mannelli F; Gianfaldoni G; Intermesoli T; Cattaneo C; Borlenghi E; Cortelazzo S; Cavattoni I; Pogliani EM; Fumagalli M; Angelucci E; Romani C; Ciceri F; Corti C; Scattolin A; Cortelezzi A; Mattei D; Audisio E; Spinelli O; Oldani E; Bosi A; Rambaldi A; Bassan R
Haematologica; 2012 Apr; 97(4):568-71. PubMed ID: 22058217
[TBL] [Abstract][Full Text] [Related]
29. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
Bassan R; Rohatiner AZ; Lerede T; Di Bona E; Rambaldi A; Pogliani E; Rossi G; Fabris P; Morandi S; Casula P; Carter M; Lambertenghi-Deliliers G; Lister TA; Barbui T
Hematol J; 2000; 1(4):226-34. PubMed ID: 11920195
[TBL] [Abstract][Full Text] [Related]
30. Three copies of isochromosome 8q in Ph+ B-cell acute lymphoblastic leukemia.
Soriani S; Fedeli F; Molteni A; Grillo G; Tedeschi A; Scarpati B; Campidelli C; Leszl A; Farioli R; De Canal G; Mura MA; Cesana C
Leuk Res; 2011 Nov; 35(11):e217-9. PubMed ID: 21767878
[No Abstract] [Full Text] [Related]
31. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.
Malumbres R; Fresquet V; Roman-Gomez J; Bobadilla M; Robles EF; Altobelli GG; Calasanz MJ; Smeland EB; Aznar MA; Agirre X; Martin-Palanco V; Prosper F; Lossos IS; Martinez-Climent JA
Haematologica; 2011 Jul; 96(7):980-6. PubMed ID: 21459790
[TBL] [Abstract][Full Text] [Related]
32. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.
Roberts KG; Gu Z; Payne-Turner D; McCastlain K; Harvey RC; Chen IM; Pei D; Iacobucci I; Valentine M; Pounds SB; Shi L; Li Y; Zhang J; Cheng C; Rambaldi A; Tosi M; Spinelli O; Radich JP; Minden MD; Rowe JM; Luger S; Litzow MR; Tallman MS; Wiernik PH; Bhatia R; Aldoss I; Kohlschmidt J; Mrózek K; Marcucci G; Bloomfield CD; Stock W; Kornblau S; Kantarjian HM; Konopleva M; Paietta E; Willman CL; Mullighan CG
J Clin Oncol; 2017 Feb; 35(4):394-401. PubMed ID: 27870571
[TBL] [Abstract][Full Text] [Related]
33. Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort.
Silva WF; Silverio A; Duarte BKL; Aguiar TF; Bendlin RM; Massaut IHB; Pagnano KBB; Velloso EDRP; Rocha V; Rego EM
Leuk Res; 2021 Nov; 110():106666. PubMed ID: 34274856
[TBL] [Abstract][Full Text] [Related]
34. “Russell-like” bodies in Philadelphia chromosome–positive B-lymphoblastic leukemia.
Bunting ST; Lew G
Blood; 2014 Apr; 123(16):2448. PubMed ID: 24860885
[No Abstract] [Full Text] [Related]
35. Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.
Lafage-Pochitaloff M; Baranger L; Hunault M; Cuccuini W; Lefebvre C; Bidet A; Tigaud I; Eclache V; Delabesse E; Bilhou-Nabéra C; Terré C; Chapiro E; Gachard N; Mozziconacci MJ; Ameye G; Porter S; Grardel N; Béné MC; Chalandon Y; Graux C; Huguet F; Lhéritier V; Ifrah N; Dombret H;
Blood; 2017 Oct; 130(16):1832-1844. PubMed ID: 28790105
[TBL] [Abstract][Full Text] [Related]
36. Philadelphia chromosome positive acute B-lymphoblastic leukemia with extreme leukocytosis.
Bhatnagar V; Emadi A
Blood; 2013 Aug; 122(7):1104. PubMed ID: 24137641
[No Abstract] [Full Text] [Related]
37. Philadelphia chromosome positive B-cell lymphoblastic lymphoma isolated to bone.
Sadrzadeh H; Huck AE; Chen YB; Hasserjian RP; Fathi AT
Leuk Lymphoma; 2013 Sep; 54(9):2052-4. PubMed ID: 23256565
[No Abstract] [Full Text] [Related]
38. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
Sadras T; Heatley SL; Kok CH; Dang P; Galbraith KM; McClure BJ; Muskovic W; Venn NC; Moore S; Osborn M; Revesz T; Moore AS; Hughes TP; Yeung D; Sutton R; White DL
Cancer Lett; 2017 Nov; 408():92-101. PubMed ID: 28866095
[TBL] [Abstract][Full Text] [Related]
39. Philadelphia chromosome-like B-acute lymphoblastic leukemia and disseminated juvenile xanthogranulomatosis with shared KRAS mutation.
Cheng J; Svoronos N; Pan M; Smith S; Vatsayan A; Jacobsohn D; Wistinghausen B
Pediatr Blood Cancer; 2024 Jun; 71(6):e30963. PubMed ID: 38523244
[No Abstract] [Full Text] [Related]
40. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Whitlock JA; Peters C; Chen-Santel C; Chia V; Dennis RM; Heym KM; Katz AJ; Kelsh MA; Sposto R; Tu H; Tuglus CA; Verma A; Vinti L; Wilkes JJ; Zubarovskaja N; Zugmaier G; von Stackelberg A; Sun W
Leukemia; 2020 Sep; 34(9):2473-2478. PubMed ID: 32094465
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
